๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer

โœ Scribed by R. Metz; M. Delgado; R. Keiling; P. Cappelaere; J. P. Armand; G. Prevot; J. L. Misset; J. Grimbert; G. Mathe

Publisher
Springer US
Year
1985
Tongue
English
Weight
301 KB
Volume
3
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose. After the EORTC Clinical Screening Group phase II trial we have conducted an "expected difference method" comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study. The reasons for similarity of action will be presented and discussed.

๐Ÿ“œ SIMILAR VOLUMES

First-line combination chemotherapy with
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer
โœ P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 312 KB

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The over